BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794-1801. [PMID: 20162463 DOI: 10.1245/s10434-010-0943-1] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Muttillo EM, Ciardi A, Saullo P, Troiano R, Masselli G, Guida M, Tortora A, Sperduti I, Marinello G, Chirletti P, Caronna R. A Prognostic Score for Predicting Survival in Patients With Pancreatic Head Adenocarcinoma and Distal Cholangiocarcinoma. In Vivo 2021;35:507-15. [PMID: 33402503 DOI: 10.21873/invivo.12285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Okada K, Kawai M, Tani M, Hirono S, Miyazawa M, Shimizu A, Kitahata Y, Yamaue H. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:648-53. [DOI: 10.1002/jhbp.109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
3 Bergquist JR, Shubert CR, Storlie CB, Habermann EB, Truty MJ. Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer. JCO 2017;35:1622-3. [DOI: 10.1200/jco.2016.71.2315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 220] [Reference Citation Analysis]
5 Distler M, Pilarsky E, Kersting S, Grützmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg. 2013;11:1067-1072. [PMID: 24161419 DOI: 10.1016/j.ijsu.2013.10.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
6 Papavasiliou P, Chun YS, Hoffman JP. How to Define and Manage Borderline Resectable Pancreatic Cancer. Surgical Clinics of North America 2013;93:663-74. [DOI: 10.1016/j.suc.2013.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
7 Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther 2016;9:7459-67. [PMID: 28003762 DOI: 10.2147/OTT.S100510] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
8 Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford) 2020;22:224-32. [PMID: 31375338 DOI: 10.1016/j.hpb.2019.06.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
9 Perri G, Prakash LR, Katz MHG. Response to Preoperative Therapy in Localized Pancreatic Cancer. Front Oncol 2020;10:516. [PMID: 32351893 DOI: 10.3389/fonc.2020.00516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, Yang C, Fan K, Huang Q, Long J, Liu L, Xu J, Lu R, Ni Q, Warshaw AL, Liu C, Yu X. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971-976. [PMID: 30131287 DOI: 10.1016/j.pan.2018.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
11 Laurent L, Sefrioui D, Bignon AL, Parzy A, Sidali S, Hassine M, Gangloff A, Galais MP, Bouhier-Leporrier K, Michel P, Di Fiore F. CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB (Oxford) 2019;21:582-8. [PMID: 30466797 DOI: 10.1016/j.hpb.2018.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Heinrich S, Lang H. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Int J Mol Sci 2017;18:E1622. [PMID: 28933761 DOI: 10.3390/ijms18081622] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
13 Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018;25:3483-3491. [PMID: 29786131 DOI: 10.1245/s10434-018-6521-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
14 Younan G, Tsai S, Evans DB, Christians KK. Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. Surg Clin North Am 2016;96:1351-70. [PMID: 27865282 DOI: 10.1016/j.suc.2016.07.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
15 Coppola A, La Vaccara V, Fiore M, Farolfi T, Ramella S, Angeletti S, Coppola R, Caputo D. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Front Oncol 2021;11:690580. [PMID: 34123859 DOI: 10.3389/fonc.2021.690580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mayer P, Giannakis A, Klauß M, Gaida MM, Bergmann F, Kauczor HU, Feisst M, Hackert T, Loos M. Radiological evaluation of pancreatic cancer: What is the significance of arterial encasement >180° after neoadjuvant treatment? Eur J Radiol 2021;137:109603. [PMID: 33618209 DOI: 10.1016/j.ejrad.2021.109603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:397. [PMID: 25543664 DOI: 10.1186/1477-7819-12-397] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
18 Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel) 2020;12:E783. [PMID: 32218346 DOI: 10.3390/cancers12040783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hartwig W, Büchler MW. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors 2013;1:41-52. [PMID: 26673950 DOI: 10.1159/000354992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
20 Brown EG, Canter RJ, Bold RJ. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma. J Surg Oncol. 2015;111:293-298. [PMID: 25330934 DOI: 10.1002/jso.23812] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
21 O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21:622-631. [PMID: 24938522 DOI: 10.1158/1078-0432.ccr-14-0365] [Cited by in Crossref: 101] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
22 Pilgrim CH, Groeschl RT, Turaga KK, Gamblin TC. Key factors influencing prognosis in relation to gallbladder cancer. Dig Dis Sci. 2013;58:2455-2462. [PMID: 23695876 DOI: 10.1007/s10620-013-2713-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
23 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 11.1] [Reference Citation Analysis]
24 Koay EJ, Katz MHG, Wang H, Wang X, Prakash L, Javle M, Shroff R, Fogelman D, Avila S, Zaid M, Elganainy D, Lee Y, Crane CH, Krishnan S, Das P, Fleming JB, Lee JE, Tamm EP, Bhosale P, Lee JH, Weston B, Maitra A, Wolff RA, Varadhachary GR. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol 2019;3:PO. [PMID: 32914036 DOI: 10.1200/PO.19.00001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Fritz S, Hackert T, Hinz U, Hartwig W, Büchler MW, Werner J. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg. 2011;98:104-110. [PMID: 20949535 DOI: 10.1002/bjs.7280] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 8.6] [Reference Citation Analysis]
26 Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford) 2015;17:942-52. [PMID: 26255895 DOI: 10.1111/hpb.12448] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
27 Distler M, Rückert F, Hunger M, Kersting S, Pilarsky C, Saeger HD, Grützmann R. Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg 2013;13:12. [PMID: 23607915 DOI: 10.1186/1471-2482-13-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
28 Takahashi H, Akita H, Wada H, Tomokuni A, Asukai K, Takahashi Y, Yanagimoto Y, Matsunaga T, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Yamamoto T, Nakanishi M, Shirayanagi M, Yamasaki T, Ohue M, Yano M, Sakon M, Ishikawa O. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer. Surgery 2018;164:1168-77. [PMID: 30146098 DOI: 10.1016/j.surg.2018.06.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
29 Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol 2017;19:667-81. [PMID: 27995549 DOI: 10.1007/s12094-016-1594-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
30 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
31 Arnone A, Laudicella R, Caobelli F, Guglielmo P, Spallino M, Abenavoli E, Martini AL, Filice R, Comis AD, Cuzzocrea M, Linguanti F, Evangelista L, Alongi P. Clinical Impact of 18F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review. Diagnostics (Basel). 2020;10. [PMID: 33287195 DOI: 10.3390/diagnostics10121042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kobayashi M, Mizuno S, Murata Y, Kishiwada M, Usui M, Sakurai H, Tabata M, Ii N, Yamakado K, Inoue H, Shiraishi T, Yamada T, Isaji S. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Pancreas 2014;43:350-60. [PMID: 24622063 DOI: 10.1097/MPA.0000000000000059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 3.9] [Reference Citation Analysis]
33 Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, Michalski C, Büchler M. Radical surgery of oligometastatic pancreatic cancer. European Journal of Surgical Oncology (EJSO) 2017;43:358-63. [DOI: 10.1016/j.ejso.2016.10.023] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 17.0] [Reference Citation Analysis]
34 Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus. 2016;5:551. [PMID: 27190750 DOI: 10.1186/s40064-016-2181-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
35 Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery 2020;168:440-7. [DOI: 10.1016/j.surg.2020.04.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Hiwatashi K, Kawasaki Y, Arigami T, Ishigami S, Kijima Y, Shinchi H, Takao S, Natsugoe S. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Pancreatology 2015;15:688-93. [PMID: 26500167 DOI: 10.1016/j.pan.2015.09.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
37 Ielpo B, Caruso R, Duran H, Diaz E, Fabra I, Malavé L, Ferri V, Alvarez R, Cubillo A, Plaza C, Lazzaro S, Kalivaci D, Quijano Y, Vicente E. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surg Oncol 2017;26:402-10. [PMID: 29113659 DOI: 10.1016/j.suronc.2017.08.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
38 Gleeson EM, Leigh N, Golas BJ, Magge D, Sarpel U, Hiotis SP, Labow DM, Pintova S, Cohen NA. Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer. Pancreas 2021;50:1163-8. [PMID: 34714279 DOI: 10.1097/MPA.0000000000001881] [Reference Citation Analysis]
39 Álvarez R, Alés I, Díaz R, de Paredes BG, Hidalgo M. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1193-8. [PMID: 28612203 DOI: 10.1007/s12094-017-1680-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
40 Kang CM, Hwang HK, Lee WJ. Pancreas club international joint symposium on pancreatic cancer 2012, Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer. Korean J Hepatobiliary Pancreat Surg 2013;17:8-13. [PMID: 26155207 DOI: 10.14701/kjhbps.2013.17.1.8] [Reference Citation Analysis]
41 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 2017;79:41-9. [PMID: 28460245 DOI: 10.1016/j.ejca.2017.03.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
43 Boeck S, Haas M, Ormanns S, Kruger S, Siveke JT, Heinemann V. Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult. Br J Cancer 2014;111:1675-6. [PMID: 24642615 DOI: 10.1038/bjc.2014.60] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
44 Hayman AV, Stocker SJ, Baker MS, Bentrem DJ, Prinz RA, Marsh RDW, Talamonti MS. CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2014;37:550-4. [DOI: 10.1097/coc.0b013e318280d5f0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Bhattacharyya T, Shinoto M, Takiyama H, Nitta Y, Koto M, Imai R, Ikawa H, Nomoto A, Tsuji H, Yamada S. Long-term outcomes of octogenarian pancreatic cancer patients treated with carbon ion radiotherapy. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.03.010] [Reference Citation Analysis]
46 Hiroshima Y, Maawy A, Zhang Y, Murakami T, Momiyama M, Mori R, Matsuyama R, Katz MH, Fleming JB, Chishima T, Tanaka K, Ichikawa Y, Endo I, Hoffman RM, Bouvet M. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore. PLoS One 2014;9:e114310. [PMID: 25463150 DOI: 10.1371/journal.pone.0114310] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 8.6] [Reference Citation Analysis]
47 Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19:2045-2053. [PMID: 22258816 DOI: 10.1245/s10434-011-2211-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
48 Appel BL, Tolat P, Evans DB, Tsai S. Current Staging Systems for Pancreatic Cancer. The Cancer Journal 2012;18:539-49. [DOI: 10.1097/ppo.0b013e318278c5b5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
49 Petrushnko W, Gundara JS, De Reuver PR, O'Grady G, Samra JS, Mittal A. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. HPB (Oxford) 2016;18:652-63. [PMID: 27485059 DOI: 10.1016/j.hpb.2016.05.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
50 Okano K, Suto H, Oshima M, Ando Y, Nagao M, Kamada H, Kobara H, Masaki T, Okuyama H, Okita Y, Tsuji A, Suzuki Y. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Jpn J Clin Oncol 2018;48:434-41. [PMID: 29590448 DOI: 10.1093/jjco/hyy033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
51 Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010;15:1205-1213. [PMID: 21045189 DOI: 10.1634/theoncologist.2010-0121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
52 Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML, Nagorney DM, Smoot RL, Farnell MB, Truty MJ. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Journal of the American College of Surgeons 2016;223:52-65. [DOI: 10.1016/j.jamcollsurg.2016.02.009] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
53 Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15:183. [PMID: 29017581 DOI: 10.1186/s12957-017-1240-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
54 Jazieh KA, Foote MB, Diaz LA Jr. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. Semin Radiat Oncol 2014;24:67-76. [PMID: 24635863 DOI: 10.1016/j.semradonc.2013.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
55 Miura JT, Evans DB, Pappas SG, Gamblin TC, Turaga KK. Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma: Improvements Needed in Population-Based Registries. Ann Surg Oncol 2013;20:4338-47. [DOI: 10.1245/s10434-013-3237-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
56 Hiroshima Y, Maawy A, Zhang Y, Murakami T, Momiyama M, Mori R, Matsuyama R, Chishima T, Tanaka K, Ichikawa Y, Endo I, Hoffman RM, Bouvet M. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC). Pancreatology 2015;15:295-301. [PMID: 25800176 DOI: 10.1016/j.pan.2015.02.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
57 Paniccia A, Gleisner AL, Zenati MS, Al Abbas AI, Jung JP, Bahary N, Lee KKW, Bartlett D, Hogg ME, Zeh HJ, Zureikat AH. Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. Ann Surg Oncol 2020;27:2961-71. [DOI: 10.1245/s10434-020-08257-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
58 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kijima Y, Ishigami S, Ueno S, Shinchi H, Natsugoe S. Predictors of early stages of histological progression of branch duct IPMN. Langenbecks Arch Surg 2015;400:49-56. [DOI: 10.1007/s00423-014-1259-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, Sho M, Honda G, Fukumoto T, Yanagimoto H, Kinoshita S, Kurata M, Aoki S, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS). Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World J Surg 2019;43:634-41. [PMID: 30298281 DOI: 10.1007/s00268-018-4814-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
60 Damanakis AI, Ostertag L, Waldschmidt D, Kütting F, Quaas A, Plum P, Bruns CJ, Gebauer F, Popp F. Proposal for a definition of "Oligometastatic disease in pancreatic cancer". BMC Cancer 2019;19:1261. [PMID: 31888547 DOI: 10.1186/s12885-019-6448-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
61 Lee W, Park Y, Kwon JW, Jun E, Song KB, Lee JH, Hwang DW, Yoo C, Kim KP, Jeong JH, Chang HM, Ryoo BY, Park SY, Kim SC. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. J Clin Med 2020;9:E1477. [PMID: 32423123 DOI: 10.3390/jcm9051477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2015;94:e751. [PMID: 25984661 DOI: 10.1097/md.0000000000000751] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
63 Patel SH, Katz MHG, Ahmad SA. The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:4104-29. [PMID: 34047859 DOI: 10.1245/s10434-021-10075-1] [Reference Citation Analysis]
64 Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. [PMID: 27247221 DOI: 10.1200/jco.2016.67.5553] [Cited by in Crossref: 195] [Cited by in F6Publishing: 80] [Article Influence: 32.5] [Reference Citation Analysis]
65 Takahashi H, Ohigashi H, Ishikawa O, Gotoh K, Yamada T, Nagata S, Tomita Y, Eguchi H, Doki Y, Yano M. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255:95-102. [PMID: 22123160 DOI: 10.1097/sla.0b013e31823d813c] [Cited by in Crossref: 79] [Cited by in F6Publishing: 28] [Article Influence: 7.9] [Reference Citation Analysis]
66 Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N, Zeh HJ 3rd. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21:4351-4358. [PMID: 25092157 DOI: 10.1245/s10434-014-3842-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 13.0] [Reference Citation Analysis]
67 Merrell KW, Haddock MG, Quevedo JF, Harmsen WS, Kendrick ML, Miller RC, Hallemeier CL. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 2016;94:561-70. [DOI: 10.1016/j.ijrobp.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
68 Pandiaraja J, Viswanathan S, Antomy TB, Thirumuruganand S, Kumaresan DS. The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas. J Clin Diagn Res 2016;10:PC06-9. [PMID: 27134925 DOI: 10.7860/JCDR/2016/17106.7398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
69 Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015;6:418-429. [PMID: 26261728 DOI: 10.3978/j.issn.2078-6891.2015.053] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
70 Kumar R, Jabbour SK. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer. J Radiat Oncol 2013;2:353-67. [DOI: 10.1007/s13566-013-0120-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
71 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Arigami T, Mori S, Ueno S, Shinchi H, Takao S, Natsugoe S. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Pancreatology 2016;16:1051-6. [DOI: 10.1016/j.pan.2016.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Jung JP, Zenati MS, Hamad A, Hogg ME, Simmons RL, Zureikat AH, Zeh HJ, Boone BA. Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma? HPB (Oxford) 2019;21:679-86. [PMID: 30501987 DOI: 10.1016/j.hpb.2018.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 2020;271:740-747. [PMID: 30312198 DOI: 10.1097/sla.0000000000003049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
74 Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncologica 2017;56:391-7. [DOI: 10.1080/0284186x.2016.1256497] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
75 Oppliger FA, Prakash LR, Newhook TE, Chiang YJ, Ikoma N, Maxwell JE, Kim MP, Vauthey JN, Lee JE, Katz MH, Tzeng CD. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Surg Oncol 2021;40:101673. [PMID: 34894620 DOI: 10.1016/j.suronc.2021.101673] [Reference Citation Analysis]
76 Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M, Ishikawa O. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013;258:1040-1050. [PMID: 23799421 DOI: 10.1097/sla.0b013e31829b3ce4] [Cited by in Crossref: 100] [Cited by in F6Publishing: 40] [Article Influence: 12.5] [Reference Citation Analysis]
77 Ward EP, Zeh Iii HJ, Tsai S. Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. Surg Oncol Clin N Am 2021;30:657-71. [PMID: 34511188 DOI: 10.1016/j.soc.2021.06.010] [Reference Citation Analysis]
78 Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World J Gastroenterol 2014; 20(42): 15564-15579 [PMID: 25400440 DOI: 10.3748/wjg.v20.i42.15564] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
79 Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg 2021;273:806-13. [PMID: 31274655 DOI: 10.1097/SLA.0000000000003442] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 21.0] [Reference Citation Analysis]
80 Yu Y, Zheng P, Chen Y, Wang B, Paul ME, Tao P, Wang D, Li H, Gu B, Gao L, Wang D, Chen H. Advances and challenges of neoadjuvant therapy in pancreatic cancer. Asia Pac J Clin Oncol 2020. [PMID: 33164329 DOI: 10.1111/ajco.13504] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Xia BT, Fu B, Wang J, Kim Y, Ahmad SA, Dhar VK, Levinsky NC, Hanseman DJ, Habib DA, Wilson GC, Smith M, Olowokure OO, Kharofa J, Al Humaidi AH, Choe KA, Abbott DE, Ahmad SA. Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol 2017;115:376-83. [DOI: 10.1002/jso.24538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
82 Rieser CJ, Narayanan S, Bahary N, Bartlett DL, Lee KK, Paniccia A, Smith K, Zureikat AH. Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis. J Surg Oncol 2021. [PMID: 34231222 DOI: 10.1002/jso.26589] [Reference Citation Analysis]
83 Li S, Xu H, Wu C, Wang W, Jin W, Gao H, Li H, Zhang S, Xu J, Zhang W, Xu S, Li T, Ni Q, Yu X, Liu L. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Med 2019;8:572-84. [PMID: 30632317 DOI: 10.1002/cam4.1957] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
84 Yun G, Kim YH, Lee YJ, Kim B, Hwang JH, Choi DJ. Tumor heterogeneity of pancreas head cancer assessed by CT texture analysis: association with survival outcomes after curative resection. Sci Rep. 2018;8:7226. [PMID: 29740111 DOI: 10.1038/s41598-018-25627-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
85 Wang W, Zhang L, Chen L, Wei J, Sun Q, Xie Q, Zhou X, Zhou D, Huang P, Yang Q, Xie H, Zhou L, Zheng S. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis. Biomed Rep. 2015;3:43-50. [PMID: 25469245 DOI: 10.3892/br.2014.376] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
86 Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020;10:500. [PMID: 32363161 DOI: 10.3389/fonc.2020.00500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
87 Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188-2196. [PMID: 23247983 DOI: 10.1245/s10434-012-2809-1] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 14.6] [Reference Citation Analysis]
88 Zaid M, Widmann L, Dai A, Sun K, Zhang J, Zhao J, Hurd MW, Varadhachary GR, Wolff RA, Maitra A, Katz MHG, Herman JM, Wang H, Knopp MV, Williams TM, Bhosale P, Tamm EP, Koay EJ. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Cancers (Basel) 2020;12:E3656. [PMID: 33291471 DOI: 10.3390/cancers12123656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J, Fleming JB. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol 2012;19 Suppl 3:S395-403. [PMID: 21701930 DOI: 10.1245/s10434-011-1839-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
91 Bednar F, Zenati MS, Steve J, Winters S, Ocuin LM, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Ann Surg Oncol 2017;24:1406-13. [PMID: 27896518 DOI: 10.1245/s10434-016-5707-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
92 Pecorelli N, Braga M, Doglioni C, Balzano G, Reni M, Cereda S, Albarello L, Castoldi R, Capretti G, Di Carlo V. Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy. J Gastrointest Surg 2013;17:488-93. [PMID: 23132627 DOI: 10.1007/s11605-012-2063-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
93 Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16:430-438. [PMID: 23991810 DOI: 10.1111/hpb.12154] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 12.2] [Reference Citation Analysis]
94 Okubo S, Kojima M, Matsuda Y, Hioki M, Shimizu Y, Toyama H, Morinaga S, Gotohda N, Uesaka K, Ishii G, Mino-Kenudson M, Takahashi S. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Sci Rep 2019;9:17145. [PMID: 31748528 DOI: 10.1038/s41598-019-53801-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Diab HMH, Smith HG, Jensen KK, Jørgensen LN. The current role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer: A systematic review. Eur J Cancer 2021;154:73-81. [PMID: 34243080 DOI: 10.1016/j.ejca.2021.05.033] [Reference Citation Analysis]
96 Nguyen KT, Kalyan A, Beasley HS, Singhi AD, Sun W, Zeh HJ, Normolle D, Bahary N. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. J Gastrointest Oncol 2017;8:556-65. [PMID: 28736642 DOI: 10.21037/jgo.2017.01.23] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
97 Ielpo B, Duran H, Diaz E, Fabra I, Caruso R, Ferri V, Malavé L, Hidalgo M, Alvarez R, Plaza C, Quijano Y, Vicente E. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol 2016;42:1394-400. [PMID: 26899943 DOI: 10.1016/j.ejso.2016.01.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
98 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
99 Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017;21:164-174. [PMID: 27778257 DOI: 10.1007/s11605-016-3265-1] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 15.3] [Reference Citation Analysis]